ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Berberine inhibits gastric cancer progression by targeting canonical Wnt/β-catenin signaling in AGS cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) progression is strongly associated with dysregulated proliferation, apoptosis resistance, epithelial-mesenchymal transition, invasion, and aberrant Wnt/β-catenin signaling. Berberine has shown anti-cancer activity in several tumor models; however, its mechanistic effects on Wnt/β-catenin-driven GC phenotypes require further clarification. This study investigated whether berberine suppresses AGS GC cell progression through inhibition of canonical Wnt/β-catenin signaling. AGS cells were treated with berberine at low, medium, and high concentrations, with CHIR99021 used for Wnt/β-catenin pathway activation and XAV939 as a pathway inhibitory control. Cell viability, proliferation, colony formation, cell cycle distribution, apoptosis, migration, invasion, EMT marker expression, β-catenin localization, TOP/FOP luciferase activity, ROS/RNS production, mitochondrial membrane potential, and glucose uptake were assessed using functional, molecular, and fluorescence-based assays. CTNNB1 knockdown was used to validate β-catenin-dependent mechanisms. Berberine reduced AGS cell viability, EdU incorporation, clonogenic survival, migration, invasion, and glucose uptake while inducing G0/G1 arrest, mitochondrial depolarization, oxidative/nitrosative stress, caspase activation, and apoptosis. Berberine increased E-cadherin and decreased N-cadherin, Vimentin, Snail, Slug, ZEB1, and MMP9, indicating suppression of EMT. Mechanistically, berberine reduced β-catenin expression, nuclear localization, TOP/FOP transcriptional activity, and downstream Wnt targets including CCND1, MYC, BIRC5, AXIN2, and MMP9. CHIR99021 partially reversed berberine-induced anti-tumor effects, whereas XAV939 and CTNNB1 knockdown mimicked or enhanced berberine activity. Berberine suppresses AGS GC cell progression by inhibiting canonical Wnt/β-catenin signaling, thereby reducing proliferation, EMT, invasion, metabolic activity, and survival while promoting cell cycle arrest and apoptosis.
Indexed as
Identifiers
42850265What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.